H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target

📌 Key Takeaways

• H.C. Wainwright maintains a Buy rating on Pyxis Oncology stock
• The firm reiterates a $7 price target for Pyxis Oncology
• The analyst's stance signals continued confidence in the company's prospects
• The recommendation is based on the firm's evaluation of Pyxis Oncology's value and potential

🏷️ Themes

Stock Analysis, Biotechnology

Entity Intersection Graph

No entity connections available yet for this article.

Source

investing.com